Group | Weight | Effect size | I2a | P | I2b | |
---|---|---|---|---|---|---|
(%) | SMD | 95% CI | (%) | (%) | ||
All experiments | 100.0 | 1.23 | 0.43, 2.03 | 89 | Â | Â |
Cancer type | ||||||
 Breast cancer | 48.6 | 2.04 | 0.87, 3.21 | 90 | 0.060 | 71.8 |
 Other cancer | 51.4 | 0.48 | − 0.65, 1.61 | 89 |  |  |
Animal species/strain | ||||||
 Nude mice | 82.3 | 1.12 | 0.26, 1.97 | 89 | 0.690 | 0 |
 Other mice/rat | 17.7 | 1.67 | − 0.9, 4.23 | 92 |  |  |
Source of MSC | ||||||
 Human bone marrow | 40.7 | 1.96 | 0.59, 3.33 | 87 | 0.330 | 12.4 |
 Other human tissue | 18.2 | 0.09 | − 1.94, 2.13 | 94 |  |  |
 Mice/rat bone marrow | 31.0 | 0.73 | − 0.72, 2.17 | 89 |  |  |
 Unclear | 10.0 | 2.15 | − 0.14, 4.34 | 85 |  |  |
Metastasis estimation | ||||||
 Fluorescence microscopy | 42.0 | 1.11 | − 0.3, 2.35 | 90 | 0.170 | 44.2 |
 Histological evaluation | 40.1 | 2.02 | 0.76, 3.29 | 88 |  |  |
 Bioluminescence | 17.9 | − 0.54 | − 2.95, 1.87 | 89 |  |  |
Cancer cell/MSC dose ratio | ||||||
 = 1 | 62.6 | 1.11 | 0.1, 2.12 | 90 | 0.030 | 72.7 |
 > 1 | 7.2 | − 0.20 | − 1.08, 0.67 | 0 |  |  |
 < 1 | 30.2 | 1.85 | 0.45, 3.24 | 80 |  |  |
Timing of MSC administration | ||||||
 Co-administration | 68.5 | 2.18 | 1.38, 2.99 | 82 | 0.001 | 94 |
 Follow-administration | 31.5 | − 1.13 | − 2.50, 0.23 | 88 |  |  |
Study length (days) | ||||||
 ≤ 42 | 59.1 | 0.32 | − 0.70, 1.35 | 91 | 0.006 | 86.7 |
 > 42 | 40.9 | 2.44 | 1.32, 3.56 | 78 |  |  |
Metastasis site | ||||||
 Lung | 81.6 | 1.80 | 0.28, 2.07 | 89 | 0.570 | 0 |
 Other tissue | 18.4 | 1.66 | 0.26, 3.07 | 73 |  |  |
Study quality category | ||||||
 Meet 9–12 criteria | 0 | – | – | – | 0.07 | 70.5 |
 Meet 5–8 criteria | 20.3 | 2.92 | 0.90, 4.94 | 90 |  |  |
 Meet 0–4 criteria | 79.7 | 0.85 | − 0.04, 1.74 | 89 |  |  |
Impact factor of journal | ||||||
 ≤ 5 | 56.8 | 0.30 | − 0.73, 1.32 | 89 | 0.004 | 87.7 |
 > 5 | 43.2 | 2.30 | 1.38, 3.22 | 74 |  |  |